Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹121.03 Cr |
| Fresh Issue | ₹121.03 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹86.00-91.00 per share |
| BSE Code | 544497 |
| NSE Code | AHCL |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Interactive Financial Services Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 164 shares and in multiples thereof
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for Proposed Expansion | 30.72 |
| 2 | Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company | 5.00 |
| 3 | Funding the working capital requirements of the Company | 43.15 |
| 4 | General Corporate Purposes | 27.03 |
| 5 | Issue Expenses | 15.13 |
| Total | 121.03 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| NET Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 40.45% |
| ROCE | 21.93% |
| Debt / Equity | 0.73% |
| RoNW | 25.51% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 5.15 | 3.86 |
| P/E (x) | 17.67 | 23.57 |
| Promoter Holding | 70.26% | 52.68% |
| Market Cap | ₹483.68 Cr. | |
